[
    [
        {
            "time": "",
            "original_text": "主力注射液营业成本增长超十倍！深交易所“拷问”易明医药",
            "features": {
                "keywords": [
                    "注射液",
                    "营业成本",
                    "增长超十倍",
                    "深交易所",
                    "拷问",
                    "易明医药"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "主力注射液营业成本增长超十倍！深交易所“拷问”易明医药",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "苑东生物：招股书数据存多处“出入” 信披漏洞百出显隐忧 经营问题",
            "features": {
                "keywords": [
                    "苑东生物",
                    "招股书",
                    "数据出入",
                    "信披漏洞",
                    "经营问题"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "苑东生物：招股书数据存多处“出入” 信披漏洞百出显隐忧 经营问题",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "步长制药销售费用占营收59%低于同行水平 商誉两年未减少转型大健康",
            "features": {
                "keywords": [
                    "步长制药",
                    "销售费用",
                    "营收59%",
                    "低于同行",
                    "商誉",
                    "转型大健康"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药",
                    "大健康"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "步长制药销售费用占营收59%低于同行水平 商誉两年未减少转型大健康",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]